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Summarv Mutation of the p53 gene is a common event in colorectal cancer. This alteration can result in
cellular accumulation of p53 and mav also induce p53 antibodies. Accumulation of p53 in tumour cells has
been associated with poor prognosis of colorectal cancer. We tested preoperative sera from 255 patients with
colorectal cancer bv enzyme-linked immunosorbent assav (ELISA). A total of 70.2% had reactivity that was
higher than the low control serum. Employing a cut-off level of 100/ of the 'high' control sample. 25.5% of
the patients wvere positise for p53 antibodies. The presence of p53 antibodies correlated with the following
prognostic factors: histological differentiation grade. shape of the tumour. and tumour invasion into blood
sessels. Patients with p53 antibodies swere shown to have decreased survival and decreased disease-free
survival. Specifically for patients with cancer stage A and BI the presence of p53 antibodies selected a
subgroup with poor prognosis.
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Colorectal cancer cells hasve accumulated several genetic
alterations (Fearon and Vogelstein. 1990). The most common
of these defects is loss of function of the tumour-suppressor
gene p53 (Lane. 1992; Vogelstein and Kinzler. 1992).
Although different mechanisms can result in loss of function
of p53. allelic loss and mutation of the other gene is most
often found (Baker et al.. 1989: Levine et al.. 1991: Vogels-
tein and Kinzler. 1992). These point mutations are associated
with p53 overexpression caused by the decreased breakdown
of the tetrameric form with mutant components (Levine et
al.. 1991). The normal level of nuclear p53 expression is
extremely low. but the aberrant accumulation of p53 in the
tumour cell is detectable with p53-specific antibodies (Rem-
vikos et al.. 1990: Bartek et al.. 1991: Lane. 1992). In colorec-
tal cancer p53 is overexpressed in 50-70% of tumours (Cun-
ningham et al.. 1992: Sun et al.. 1992; reviewed by Harris
and Hollstein. 1993).
Because mutation in the p53 gene and the consequent
overexpression of p53 are associated with tumour tissue.
both. wrild-type and mutant p53 may act as targets of
tumour-specific humoral and cellular immune responses. p53-
specific antibodies in the sera of patients have been studied in
breast cancer (Crawford et al.. 1982; Davidoff et al.. 1992.
Schlichtholz et al.. 1992: Mudenda et al.. 1994). in lung
cancer (Winter et al.. 1992: Schlichtholz et al.. 1994). in
B-cell lymphoma (Caron de Fromentel et al.. 1987) and more
recently in various other types of cancer (Labrecque et al.,
1993: Lubin et al.. 1993: Angelopoulou et al.. 1994). In
breast cancer. a p53 antibody response was found to be an
indicator of poor prognosis (Schlichtholz et al.. 1992:
Mudenda et al.. 1994).
Using an ELISA. we tested the serum samples taken
preoperatively from 255 patients that participated in the
CRAB clinical trial on the relationship between blood trans-
fusion and colorectal cancer prognosis (Houbiers et al..
1994). for the presence of p53 antibodies. The correlations
between the presence of serum antibodies against p53 and
prognostic factors of colorectal cancer and patient survival
were investigated.
Patients and methods
Patients
Preoperative sera of 255 patients were tested for p53
antibodies. The colorectal cancer patients were enrolled in
the CRAB clinical trial bv seven different hospitals between
1987 and 1991 (Houbiers et al.. 1994). Data on patient
history. surgery. tumour pathology. clinical complications
and outcome during an average follow-up of 36 months were
available. A total of 231 sera were drawn from patients
operated upon with curative intent. while 24 sera were from
patients with known metastatic disease at the time of surgery.
.4ssaX
The detection of p53 antibodies in patient sera was per-
formed with a commercially available sandwich enzyme-
linked immunosorbent assay (ELISA. p53-AK ELISA. cat.
no. diaO301E. Dianova. Hamburg. Germany). The assay was
performed according to the manufacturer's instructions and
has the following specifications: 1:100 diluted patient serum
was added for 60 min at 37C to microtitre wells coated with
recombinant p53. After washing. goat anti-human IgG
antibody conjugated with peroxidase was added for 30 mi at
37°C; finally the substrate 3. 5. 3. 5-tetramethylbenzidine
(TMB) was added for 30 min. The enzymatic process was
stopped by adding 2 N hydrogen chloride. Light absorption
was measured at 450 nm on a photospectrometer (Titertek
Multiskan).
This ELISA was validated by comparing the ELISA
results of sera from cancer patients and non-cancer patients
with results obtained from Western blotting with recom-
binant p53: the results of these sera showed a high concor-
dance (H Zentgraf and PR Galle 1994. Heidelberg, personal
communication). A total of 379 patients without tumours
were negative in the p53 antibody assay (Mfiller et al. 1994).
The ELISA absorption data of our study were correlated
with the manufacturer's control sera ('low' or 'high' concent-
ration of p53 antibodies) by the following formula. which
was designated the p53 antibody titre index (TI)
p53-TI =
patient sample absorption
- absorption of low control
absorption of high control
- absorption of low control
x 100% Correspondence: JGA Houbiers
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The absorption results of sera from our own serum bank.
added to control intertest variation showed good concor-
dance between the different assays. Additionally, testing of
the 'medium' control serum that was provided by the
manufacturer resulted in p53-TIs in the narrow range from
310% to 350% in all assays. The sera of two patients that were
excluded from the CRAB study because of a benign colon
tumour had a p53-TI of < 10%. The sera of40 healthy blood
donors also had a p53-TI of < 10%.
Immunohistochemistrv
A three step indirect immunoperoxidase technique on frozen
4jtm-thick colorectal carcinoma tissue sections was per-
formed as described earlier (Ravenswaay Claasen Van et al..
1992). The monoclonal antibodies PAb 122 (Gurney et al..
1980). D07 (Vojtesek et al., 1992) and the polyclonal
antiserum CMI (Bartek et al.. 1991) were used to detect
cellular accumulation (overexpression) of p53 and appeared
concordant in all sections. except that PAb 122 stained more
weakly and fewer cells were positive per section compared to
the other two antibodies. From different parts of a resected
tumour, on average five pieces of tissue were taken; if one or
more pieces showed overexpression of p53 that tumour was
considered positive for p53 accumulation. The results of
immunohistochemical staining for p53 of colorectal car-
cinomas is further described elsewhere (Houbiers et al.. sub-
mitted).
Anal}sis
Using the Fisher's test for 2 x 2 tables (Fisher's exact test).
the presence of p53 antibodies was correlated to the follow-
mg prognostic factors of colorectal cancer: cancer stage
[Dukes' classification modified according to Astler and Coller
(1954)], histological differentiation, location of the tumour.
tumour infiltration into adjacent organs. tumour size, tumour
shape. tumour invasion of lymph vessels or blood vessels.
sex, and a history of blood transfusion, blood groups (ABO.
rhesus). Correlations between the presence of p53 antibodies
and disease-free survival, overall survival, and risk of cancer
recurrence were analysed using the Kaplan-Meier method
and log-rank tests (for details. Houbiers et al.. 1994). Fur-
thermore the association of p53 antibodies with the accu-
mulation of p53 in tumour cells, as detected by immunohis-
tochemistry on autologous tumour samples. was analysed
with the Fisher's exact test.
Results
Of the 255 tested preoperative sera from patients with colo-
rectal cancer, 70.2% had a p53-antibody titre index (p53-TI)
that was higher than the manufacturers 'low' control serum
(i.e. >0%. Table I). When results of p53-TI < 10% were
regarded as absence of p53 antibodies. 25.5% of the sera
were positive (Table I). The cut-off level of 10% was not
arbitrarily chosen; samples with a lower absorption than the
'low control' that was provided by the manufacturer had a
p53-TI between - 10% and 0%. Furthermore, the relevance
of the I0% cut-off level was confirmed by the results of ten
sera that were tested in an unmarked order for p53
antibodies using immunoblotting with recombinant p53
(Western blotting). The six sera that had a p53-TI < 10%
were negative by Western blotting (Figure 1); the two sera
that appeared low or intermediate positive (+ or + +) by
Western blotting scored intermediate positive by ELISA; the
other two sera scored triple plus on the semiquantitative
Western blot scale and had a p53-TI>60% by ELISA.
The tumours of 20 of the 255 patients had been
immunohistochemically stained for HLA antigens and cell-
ular p53 accumulation (overexpression of p53). The associa-
tion between tumours with p53 overexpression and serum
p53 antibodies was significant: 7 out of the 12 patients with
Table I p53 antibodies in 255 colorectal cancer patients
p53-TP
(percentage of Percentage Cumulative percentage
high control) n ofpatients ofpatients
1< 0 76 29.8 29.8
1 10 114 44.7 74.5
11- 20 20 7.8 82.4
21- 30 12 4.7 87.1
31- 40 8 3.1 90.2
41- 50 1 0.4 90.6
51- 60 4 1.6 92.2
61- 70 7 2.7 94.9
71- 80 1 0.4 95.3
81- 90 1 0.4 95.7
91 -100 0
100-110 4 1.6 97.3
110- 120 0
120-130 2 0.8 98.0
130- 140 2 0.8 98.8
140-150 0
150-160 1 0.4 99.2
160-170 1 0.4 99.6
170-180 1 0.4 100.0
ap53-TI. (patient sample - low control) (high control - low
control) x 100%.
tumours showing p53 overexpression had a p53-TI> IO%.
while only one out of the eight without p53 overexpression
had antibodies (P = 0.05).
Correlation ofp53 antibodies Xwith prognosticfactors
Table II gives a summary of the correlation of the p53-
antibody status to known prognostic factors for colorectal
cancer. The analyses with the cut-off level for the antibody-
negative status on p53-TI < 10% is shown. A significant
association was found with histological grade. shape of the
tumour, invasion of the tumour into blood vessels and the
Quetelet index (i.e. the quantitative relation to the ideal body
weight). Division of the p53-TI scale into two classes (S 0%,
>0%). three (<10%. 10-33%, and >33%) or into four
(<10%, 10-33%, 33-80%. >80%) classes resulted in
similar distnrbutions.
The cancer stage was weakly associated with p53 anti-
bodies: comparison of p53 antibody status of patients with
cancer stage A or B to those with stage C resulted in 21% vs
31% p53 antibody positivity (P = 0.09); while the division of
the p53-TI into four classes revealed an association with a
P-value of 0.06.
No asssociation was found between p53 antibody status
and any of the following factors: age, a history of pregnancy,
history of blood transfusion, ABO blood group system,
rhesus blood group system, sex, a history ofcholecystectomy,
diabetes, chronic aspecific lung disease, extension of the
tumour into other organs, ulcerative tumour, presence of
metastatic disease. lymph vessel involvement or size of the
tumour.
Follow-up andp53 antibodies
Colorectal cancer prognosis was expressed in terms of overall
survival, disease-free survival and disease-free period at 3
years of follow-up and was analysed on the basis of Kap-
lan-Meier curves as previously reported (Houbiers et al..
1994). Associations between cancer prognosis and p53
antibodies were observed (Table III). We further analysed the
association of p53 antibody status with prognosis within the
subgroups of the major prognostic variable of colorectal
cancer: the cancer stage. Within the subgroup of patients
with cancer stage A (invasion limited to the mucosa or
submucosa) or B1 (tumour progression into. but not
through, the muscle layer of the large bowel), those who had
induced p53 antibodies showed a significantly reduced sur-
vival. Analyses of the subgroups with cancer stage B2 and
cancer stage C revealed no significant results.No. 1 2 3 4 5
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7 10 11 13 17 C
<- p53
Western blot +++ - ++ - ++(+ +
p53-TI (%) 174 7 38 -3 75 3 5 6 6 40
Fgwe 1 Western blot analysis was performed on ten patient sera to confirm the results of the ELISA. The recombinant p53
molecules (lane C) have run through the gel until the mark at the right-hand side and were labelled with anti-p53 antibody (p53).
The sera with the numbers (No.) 2, 4, 7, 10, 11 and 13 can be considered negative by Western blot (-); in the ELISA they scored
similarly negative (p53-TI < 10%). The sera numbered 3 and 17 appeared low or intermediate positive (+ or+ +) and scored
intrmediate positive by ELISA (p53-TI). The other two sera (1 and 5) scored++ + on the semiquantitative Western blot scale
and had a p53-TI >60% by ELISA.
TableH p53 antibodies and prognostic factors of colorectal cancer
p53-TI (1O)a
Factor + - P-valueb
Rhesus factor' Number ofpatients
Positive 12 30 0.63
Negative 51 153
Cancer stage
A+Bl 16 49 0.17
B2 19 79
C 27 59
Histological grade3
Well differentiated 4 15 0.02
Moderately differentiated 40 136
Poorly differentiated 18 22
Shape of the tumours4
Stalked or sessile 16 72 0.04
Flat or circular 41 97
Invasion of blood vessels5
No 53 173 0.02
Yes 12 15
Quetelet index6
S 21 7 40 0.01
22-26 32 70
>27 15 19
&p53 antibody status is positive (+ ) ifp53-TI > 10%. bP_value of
one-sided Fisher's exact test (2 x 2) orchi-square (2 x 3). Data missing
from patients: 1,9; 2,6; 3,20; 4,29; 5,2 (blood vessels); 6,72.
Multivariate analysis
Multivariate survival analysis (i.e. Cox regression analysis)
was employed to establish the independent prognostic value
of the p53 antibody status. In a predictive model with the
variables cancer stage, extension of the tumour, histological
grade, and tumour invasion into blood vessels and survival,
disease-free survival or disease-free period as outcome vari-
able, the p53-antibody status appeared not to add
significantly to the model.
Table III p53 antibody status and colorectal cancer prognosis
Division on basis of p53-TI (JO)a
p53 antibody status +
(n) (n) (n) P-value
All patients (249) (63) (186)
Overall survival' 61 68 0.35
Disease-free survivalb 51 58 0.50
Disease-free periodb 59 63 0.73
Curativec surgery (226) (58) (168)
Overall survival 64 72 0.22
Disease-free survival 56 64 0.26
Disease-free period 64 70 0.42
Cancer stage A or Bi (64) (16) (48)
Overall survival 75 88 0.04
Disease-free survival 69 81 0.04
Disease-free penod 87 88 0.22
Zp53 antibody status ispositive ( + ) ifp53-TI > 10%. bPercentage of
patients alive or disease free at 3 years of follow-up based on
Kaplan-Meier curves; P-value of log-rank test. cNo evidence of
remaining malignant tissue.
Disaussion
Using ELISA, we studied the presence of p53 antibodies in
preoperatively collected serum of 255 patients with colorectal
cancer. A total of 70.2% of the patients had reactivity above
the 'low' control (Table I); when employing a cut-off of
p53-TI < 10%, 25.5% of the patients were positive for p53
antibodies. The cut-off level of 10% was not arbitrarily
chosen; sera with ELISA results below the 'low control'
ranged from p53-TI -10% to 0% and the six sera with
p53-TI < 10% that additionally were tested with immunob-
lotting were negative for p53 antibodies.
The only study reporting on p53 antibodies in colorectal
cancer patients used different assays and detected a positive
antibody status in 13 patients (16%) out of 82 tested
(Angelopoulou et al., 1994). That report, however, gives no
clinical or pathological details on the patient group, nor does
it correlate the results with prognosis.
The observed associations between p53 antibody positivitySerum p53 anibodies and coorec cance
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and factors related to poor prognosis of colorectal cancer
suggest that intracellular p53 accumulation is not sufficient to
elicit a humoral response, but that free p53 has to be present-
ed to the immune system. Thus, p53 antibodies seem an
expression of aggressive and extended tumours. We found
that low differentiation grade, flat or circular tumour shape,
tumour invasion into blood vessels, and lymph node metas-
tases were associated with p53 antibodies. The correlation of
the Quetelet index (i.e. the quantitative relation to the ideal
body weight) and the induction of p53 antibodies is difficult
to interpret (Table II). Cachectic patients may have a
decreased immune reactivity, while overweight patients might
notice symptoms of colorectal cancer only in a more ad-
vanced stage.
The correlation of p53 antibodies with prognostic factors
of colorectal cancer is reflected in the correlation with sur-
vival rates when univariately analysed (Table III). When
tested in a multivariate survival analysis, p53-antibody status
appeared to be insignificant and could not add any predictive
value to a model with the major prognostic factors. This
analysis indicates that p53 antibody status is dependent on
the other factors. Upon analysis of subgroups, p53 antibody
status was only associated with the prognosis for patients
with an early stage of the disease (i.e. cancer stage A or B1).
For these patients, p53-antibody status may provide addi-
tional information. An advanced stage of colorectal cancer at
time of diagnosis apparently represents aggressive tumours.
In these cases p53 antibody status lacks prognostic value.
Schlichtholz et al. (1992) and Mudenda et al. (1994) found
a correlation between the presence of p53 antibodies and
histological grade of the tumour in breast cancer patients: no
correlations were observed with cancer stage. tumour size.
lymph node involvement, or risk of cancer recurrence. The
only other study that investigated the correlation of p53
antibodies with patient prognosis or prognostic factors did
not find such associations in a group of lung cancer patients
(Winter et al., 1992). In 1993, Winter et al., reported on a
significant association between improved survival of lung
cancer and the presence of serum antibodies against
autologous tumour cell protein extracts. Two of the 21
positive sera from these 36 tested patients appeared specific
for p53. These data suggest that an anti-tumour immune
response, represented by the detected antibodies, may affect
tumour growth.
With one exception, no p53 antibodies were found in the
serum of patients with a tumour that lacked immunohis-
tochemically detectable overexpression of p53. This result is
comparable to observations that only tumours with missense
mutations of p53, resulting in p53 overexpression, elicit p53
antibodies (Davidoff et al., 1992; Winter et al., 1992; Lubin
et al., 1993). The origin of detectable p53 antibodies in serum
from one patient with a primary tumour lacking p53 overex-
pression is unclear. This autoantibody induction may be due
to the unusual presentation of large amounts of wild-type
p53 from necrotic large tumours or metastases. It is also
conceivable that the p53 gene is mutated and p53 - although
the altered protein does not accumulate and thus is undetec-
table by immunohistochemistry - is presented to the immune
system (T-helper cells) differently or in higher concentrations
resulting in antibody induction.
Although mutations throughout the p53 gene can result in
stabilisation and overexpression, the study by Davidoff et al.
(1992) found that only tumours with complexes between p53
and a 70 kDa heat shock protein can elicit p53 antibodies.
These complexes were primarily found in tumours with p53
mutations in exons 5 and 6, whereas tumours of patients
without p53 antibodies exclusively displayed mutations in
exons 7 and 8. This finding gives an explanation for the low
frequency of p53 antibodies in patients with p53 overexpress-
ing tumours.
The induction of p53 antibodies is an autoimmunisation
process caused by the presentation of accumulated p53 to the
immune system (Lubin et al.. 1993). which apparently has
not become tolerant to this self-protein. The detection of IgG
class p53 antibodies indicates that CD4+ T-helper cells have
been activated. These T cells are required to provide help for
activation of cytotoxic T cells and may be used for p53-
directed immunotherapy. Indeed, we have been able in vitro
to induce cytotoxic T cells specific for wild-type and mutant
p53 peptides (Houbiers et al.. 1993).
A protective humoral or cellular immune response. how-
ever, has not been established in the studied patients. since
the presence of p53 antibodies was correlated with poor
prognosis. Therefore, p53 antibodies must be considered a
paraneoplastic phenomenon that can merely be used as a
marker for bad prognosis of colorectal cancer. The presence
of p53 antibodies may identify subgroups with poor prog-
nosis among patients with an early stage of cancer that may
need additional therapy. Its value for decisions in the man-
agement of colorectal cancer patients is still to be deter-
mined.
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